Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zometa Retention in Multiple Myeloma and Breast Cancer
NCT00760370Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Dec 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in multiple myeloma (MM), breast cancer, sponsored by Vejle Hospital. Started Dec 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
multiple myeloma (MM)breast cancer
Beyond the preview
Go deeper on NCT00760370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760370.